
Cat. #162462
MCF7 rho-0 cell line
Cat. #: 162462
Availability: 16-18 Weeks
Organism: Human
Tissue: Breast
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Mikhail Alexeyev
Institute: University of South Alabama
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: MCF7 rho-0 cell line
- Cancer type: Breast cancer
- Cancers detailed: Adenocarcinoma
- Parental cell: MCF7
- Organism: Human
- Gender: Female
- Tissue: Breast
- Disease: Cancer
- Morphology: Epithelial
- Growth properties: Adherent
- Crispr: No
- Conditional: No
- Receptors of note: Estrogen and progesterone receptor positive, HER2 negative.
- Description: The MCF7 rho-0 cell line was derived from the parental MCF7 cell line by prolonged treatment with an inhibitor of mtDNA replication. MCF7 rho-0 lacks mitochondrial DNA (mtDNA) and is useful for studies related to the oxidative phosphorylation system (OXPHOS) or the effects of different mtDNA mutations (as recipient of mtDNA). This cell line can therefore be used to evaluate the contribution of OXPHOS to breast cancer induction, progression and metastasis.
- Application: Can serve as recipients of mtDNA in cybrid formation experiments.
- Production details: These cells were derived from the parental MCF7 cell line by prolonged (69 days) treatment with ethidium bromide, an inhibitor of mtDNA replication. The resulting cell line retains the STR profile of the original parental cell line. However, it is unable to conduct oxidative phosphorylation (OXPHOS).
- Biosafety level: 1
- Recommended controls: Wild type MCF7 cells
Target Details
- Target: Does not express any of the 13 mtDNA-encoded proteins.
- Target background: mtDNA-encoded proteins are essential for oxydative phosphorylation. This cell line is unable to perform oxydative phosphorylation, which is essential for tumor progression.
Applications
- Application: Can serve as recipients of mtDNA in cybrid formation experiments.
Handling
- Format: Frozen
- Growth medium: High-glucose DMEM (4.5 g/l glucose) supplemented with 20% fetal bovine serum (FBS), 1 mM sodium pyruvate, 50 μg/mL uridine, 50 μg/mL gentamycin
- Temperature: 37°C
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Initial handling information: Upon arrival, store in liquid nitrogen or at -80°C (for up to two weeks). Thaw in a 37°C water bath, mix with 10 ml of fresh growth medium, spin down at 300g, resuspend in 10 ml of fresh medium, and transfer into 100 mm TC treated culture plate, which should be incubated at 37°C with 5% CO2, humidified.
- Subculture routine: Trypsinize with 0.05% trypsin for 5-10 min at 37°C, neutralize trypsin with fresh medium and split 1:3 every 7-14 days.
- Cultured in antibiotics: Yes, gentamycin 50 ug/ml
- Mycoplasma free: Yes
- Str profiling: STR profile is available on request

![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)


